Feasibility of switching anti-tumour necrosis factor-alpha therapy in patients with rheumatois arthritis

被引：0
|
作者：
Walsh, C. A. E. [1 ]
Minnock, P. [1 ]
Slattery, C. [1 ]
Kennedy, N. [1 ]
Veale, D. J. [1 ]
Bresnihan, B. [1 ]
FitzGerald, O. [1 ]
机构：
[1] St Vincents Univ Hosp, Dept Rheumatol, Dublin, Ireland
来源：
RHEUMATOLOGY | 2006年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I52 / I52
页数：1
相关论文
共 50 条
  • [31] Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
    Antonios Stavropoulos-Kalinoglou
    Giorgos S Metsios
    Vasileios F Panoulas
    Peter Nightingale
    Yiannis Koutedakis
    George D Kitas
    Arthritis Research & Therapy, 14
  • [32] Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
    Stavropoulos-Kalinoglou, Antonios
    Metsios, Giorgos S.
    Panoulas, Vasileios F.
    Nightingale, Peter
    Koutedakis, Yiannis
    Kitas, George D.
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (04)
  • [33] Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
    MacMullan, Paul A.
    Madigan, Anne M.
    Durcan, Laura J.
    Egan, Karl
    Bagaglia, Paola M.
    Kenny, Dermot
    McCarthy, Geraldine M.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S625 - S625
  • [34] Salmonella enterica Arthritis in a Patient with Rheumatoid Arthritis Receiving Anti-tumour Necrosis Factor Therapy
    Bubonja-Sonje, M.
    Rubinic, D.
    Anic, F.
    Novak, S.
    Vuckovic, D.
    Abram, M.
    WEST INDIAN MEDICAL JOURNAL, 2013, 62 (03): : 270 - 272
  • [35] The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-α therapy
    Bingham, SJ
    Buch, MH
    Tennant, A
    Emery, P
    RHEUMATOLOGY, 2004, 43 (03) : 364 - 368
  • [36] Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
    Brennan, FM
    Browne, KA
    Green, PA
    Jaspar, JM
    Maini, RN
    Feldmann, M
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (06): : 643 - 650
  • [37] Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
    Cavazzana, I.
    Franceschini, F.
    Danieli, E.
    Airo, P.
    Cattaneo, R.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 : S13 - S13
  • [38] Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
    I Cavazzana
    F Franceschini
    E Danieli
    P Airò
    R Cattaneo
    Arthritis Research & Therapy, 7
  • [39] Anti-tumour necrosis factor (TNF)-α therapy (etanercept)
    Maya Buch
    Arthritis Research & Therapy, 4 (1)
  • [40] Anti-tumour necrosis factor therapy in the West Midlands
    Bartram, D
    Sheeran, T
    Price, T
    Mulherin, D
    RHEUMATOLOGY, 2004, 43 (03) : 400 - 400
12345